In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 21 to 30 of 132

Sort by

Keyword or reference number: cancerRemove Keyword or reference number: cancer filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment	Health technology evaluation	TBC
Colon cancer (adjuvant) - irinotecan [ID379]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance	TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]	Technology appraisal guidance	TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]	Technology appraisal guidance	TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance	TBC

Results per page

10
25
50
All